CHMP backs a label change for Janssen's myeloma bispecific Talvey

What happened

On 15 October 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for Talvey (talquetamab), held by Janssen-Cilag International NV ^[1]. A CHMP positive opinion is a recommendation, not a European Commission decision and not an approval. The EMA variation page confirms the opinion and the holder, and nothing more: it does not state whether the change adds a new indication, moves the drug to an earlier line, or adjusts posology ^[1].

That distinction matters because the louder version of this story is not in the primary record. News headlines dated 16 October 2026 characterise the action as backing talquetamab plus daratumumab in earlier-line relapsed or refractory myeloma. Those headlines sit behind aggregator links Prognyx could not open, and the EMA record does not carry that detail.

Why it matters

Talvey today is a late-line drug. Its US label covers relapsed or refractory multiple myeloma after at least four prior lines, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, under accelerated approval based on response rate and durability ^[2]. Any move toward earlier lines in Europe enlarges the treatable population and changes where a GPRC5D-directed agent sits against the anti-CD38 and BCMA options that dominate earlier therapy.

Janssen has signalled this direction itself. Johnson & Johnson's Q2 2026 results, filed 15 July 2026, list "TALVEY plus DARZALEX FASPRO in earlier-line relapsed or refractory multiple myeloma" among the pipeline data meant to fortify future growth ^[4]. So the ambition is on the record from the sponsor, even if the specific content of the 15 October CHMP opinion is not. Read together, the J&J statement and the headlines point the same way; the primary EMA document does not yet close the gap.

Who is exposed

Genmab carries direct economic exposure. Talvey is one of six FDA-approved, royalty-bearing products from Genmab's antibody-platform partnerships, alongside DARZALEX, Kesimpta, TEPEZZA, RYBREVANT and TECVAYLI; those six generated roughly $18 billion in aggregate partner net sales in full-year 2024 ^[5]. A wider Talvey label feeds that royalty stream.

Sequencing is the second-order question for cell therapy. Legend Biotech's January 2026 JPM presentation notes that NCCN guidelines recommend talquetamab as a bridging therapy before CAR-T, to keep relapsed or refractory patients eligible for CARVYKTI ^[6]. If talquetamab moves earlier, the bridge-to-CAR-T framing has to be re-examined, because a drug used in earlier lines is harder to reserve as a pre-CAR-T bridge.

What to watch next

The near-term calendar is regulatory. A CHMP positive opinion normally precedes a European Commission decision; on the standard EU clock the Commission typically acts within roughly two months, which would place a binding EU decision around mid-December 2026. Prognyx flags this as its own estimate from the usual CHMP-to-Commission interval, not a date the EMA record supplies ^[1].

On the clinical side, Janssen's Phase 3 study comparing talquetamab-pomalidomide and talquetamab-teclistamab against EPd/PVd in relapsed or refractory myeloma (NCT06208150, 838 patients) is active but no longer recruiting, with a primary completion date of 1 April 2026 ^[7]. A Phase 1 combination-regimen study is also active but no longer recruiting ^[8]. A Phase 2 study of infliximab for cytokine release syndrome prophylaxis during teclistamab or talquetamab is recruiting ^[9]. Two pre-approval access programs are closed out: one no longer available ^[11], one marked approved for marketing ^[12].

The now-what

For a BD or R&D lead in myeloma, three moves. First, treat the earlier-line Talvey-daratumumab combination as a stated Janssen priority ^[4] but an unconfirmed regulatory event, and do not model a European earlier-line indication until the Commission decision text lands. Second, revisit any plan that leans on talquetamab as a late-line or bridge-only agent ^[6]; the direction of travel is earlier.

Verdict: medium-term watch, not an immediate threat. The window to act is the roughly eight weeks to a likely European Commission decision; use it to confirm the label scope before repricing any competing program.

What Prognyx could not verify

The exact clinical content of the CHMP variation, including whether it covers talquetamab plus daratumumab in earlier lines, is not stated in the EMA record available here ^[1]. No Janssen press release, EMA meeting highlights or EPAR update was available to confirm the new wording, and no J&J filing specifically announcing this CHMP opinion is in the record. The GPRC5DxCD3 mechanism is as described in a September 2026 Hematology cohort report that Prognyx could not open directly ^[13]. No sourced data on teclistamab's or elranatamab's competitive position was available, so this briefing makes no claim about them.